INT267577

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 2006
Last Reported 2006
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 5
Disease Relevance 3.84
Pain Relevance 2.71

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (ERC1) cytoplasm (ERC1)
Anatomy Link Frequency
capsule 1
ERC1 (Homo sapiens)
Pain Link Frequency Relevance Heat
carbamazepine 815 100.00 Very High Very High Very High
Central nervous system 30 97.22 Very High Very High Very High
anticonvulsant 5 83.36 Quite High
headache 10 67.44 Quite High
antidepressant 10 16.88 Low Low
depression 40 5.00 Very Low Very Low Very Low
sodium channel 10 5.00 Very Low Very Low Very Low
adenocard 5 5.00 Very Low Very Low Very Low
Neurotransmitter 5 5.00 Very Low Very Low Very Low
tolerance 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Epilepsy 50 99.68 Very High Very High Very High
Diplopia 10 99.08 Very High Very High Very High
Confusion 5 98.80 Very High Very High Very High
Manic Depressive Disorder 295 98.08 Very High Very High Very High
Ataxia 10 98.02 Very High Very High Very High
Vertigo 5 97.86 Very High Very High Very High
Sleep Disorders 10 97.68 Very High Very High Very High
Dizziness 10 82.56 Quite High
Vomiting 10 80.72 Quite High
Pruritus 5 78.32 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The current review will examine data for a twice-daily extended-release capsule formulation of CBZ (CBZ-ERC) (Shire Pharmaceuticals, Wayne, PA, USA) that contains three different types of beads (immediate release, extended release, and enteric release).
Localization (release) of ERC in capsule associated with carbamazepine
1) Confidence 0.78 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671727 Disease Relevance 0.46 Pain Relevance 0.32
To further define the improved tolerability of CBZ-ERC, a 3-month, multicenter, open-label study employed the Adverse Event Profile (AEP) questionnaire to measure the adverse event changes associated with switching adult patients with epilepsy from immediate-release CBZ to equal daily doses of CBZ-ERC.
Localization (release) of ERC associated with epilepsy and carbamazepine
2) Confidence 0.73 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671727 Disease Relevance 0.67 Pain Relevance 0.68
Analysis of the AEP total scores at end point showed that patients converted to CBZ-ERC exhibited statistically significant mean decreases in all common CNS side effects (sedation, vertigo, ataxia, difficulty in coordination, confusion, and diplopia) as a result of transitioning from immediate-release CBZ to CBZ-ERC (p < 0.0001 for all side effects).
Localization (release) of ERC associated with ataxia, diplopia, vertigo, central nervous system, sleep disorders, confusion and carbamazepine
3) Confidence 0.73 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671727 Disease Relevance 0.76 Pain Relevance 0.67
The pooled analysis of safety data from the two 3-week trials indicated that CBZ-ERC was generally well tolerated in both manic and mixed bipolar patients.
Localization (tolerated) of ERC associated with carbamazepine
4) Confidence 0.73 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671727 Disease Relevance 0.99 Pain Relevance 0.47
Nonetheless, because epilepsy and bipolar disorder are separate entities with distinct pathophysiological mechanisms, the potential merits of CBZ-ERC in comparison with immediate-release CBZ remain to be examined in a population specifically consisting of patients with bipolar disorder.
Localization (release) of ERC associated with epilepsy, manic depressive disorder and carbamazepine
5) Confidence 0.73 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671727 Disease Relevance 0.96 Pain Relevance 0.58

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox